Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5):440-53

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  UPDATE ON THE DIAGNOSIS AND TREATMENT OF DIFFERENTIATED THYROID CANCERFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5):440-53

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Molecular pathology of differentiated thyroid cancer

Greco A. 1, Borrello M. G. 1, Miranda C. 1, Degl’Innocenti D. 1, Pierotti M. A. 2

1 Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine I RCCS Foundation, National Tumor Institute, Milan, Italy 2 Scientific Directorate, IRCCS Foundation, National Tumor Institute, Milan, Italy


FULL TEXT  


Thyroid cancer is the most common endocrine malignancy; it accounts for approximately 1% of all new case of cancer each year, and its incidence has increased significantly over the last few decades. The majority of thyroid tumors originate from follicular epithelial cells. Among them, papillary (PTC) and follicular carcinomas (FTC) represent the most common forms of differentiated thyroid cancer and account for approximately 80% and 15% of all cases, respectively. Specific genetic lesions are associated to each thyroid tumor histotype: BRAF mutations and RET/PTC and TRK oncogenes have been detected in PTC, whereas FTC is characterized by PAX8/PPARg rearrangements and RAS mutations. In this review we summarize studies on the molecular biology of the differentiated thyroid tumors, with particular interest in the associated genetic lesions and their role in thyroid carcinogenesis. We also report recent findings on gene expression and miRNA profiles of PTC and FTC.

top of page

Publication History

Cite this article as

Corresponding author e-mail

angela.greco@istitutotumori.mi.it